ASTROTECH Corp

Astrotech Corporation operates in the mass spectrometry and gas chromatography industry, commercializing its proprietary Astrotech Mass Spectrometer Technology platform through application-specific wholly owned subsidiaries. The company targets high-demand environments including airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations. The intellectual property includes 17 ¹ patents granted along with extensive trade secrets. Since the TRACER 1000 was certified by the European Civil Aviation Conference in 2019, customers have deployed devices in approximately 34 ² locations in 16 ³ countries throughout the United States of America, Europe, and Asia.

Primary competition for the TRACER 1000 comes from IMS-based ETDs sold by companies much larger than Astrotech with well-established sales forces and a wider range of security products. For AgLAB, the only direct competition identified is high performance liquid chromatography. Pro-Control faces competition from legacy OEMs including ABB, Siemens, Emerson, Thermo Fisher Scientific, Endress and Hauser, Perkin Elmer, Mettler Toledo, PAC LP, Horiba Process Analyzers, and AMETEK. EN-SCAN competitors include established providers of portable GC-MS devices. The company differentiates through near-zero false alarms, limitless library expansion, high uptime, fast cleardown, and confirmatory technology for 1st Detect, and through proprietary ATi Gas Chromatograph and AMS Technology for EN-SCAN.

Astrotech generates revenue through product sales of mass spectrometry and gas chromatography equipment, related consumables, recurring maintenance and extended warranty services, repairs, training, and government grants. Revenue is recognized from product sales upon shipment or delivery when control transfers to the customer. The company employs both direct sales and channel sales through distributors. For the fiscal year ended June 30, 2025, the company had four material customers that comprised substantially all of its $1.0 million ⁴ in revenue. Total revenue was approximately $920 thousand ⁵ in point in time and $130 thousand ⁶ over time for 2025.

The company operates through six wholly owned subsidiaries. Astrotech Technologies, Inc. owns and licenses the AMS Technology platform to four wholly-owned subsidiaries on an exclusive basis. 1st Detect Corporation has developed the TRACER 1000, the world's first MS based ETD certified by ECAC and approved by TSA for air cargo, and launched the enhanced TRACER 1000 Narcotic Trace Detector on March 10, 2025. AgLAB, Inc. has developed the AgLAB 1000 series of mass spectrometers for the hemp and cannabis markets, with the AgLAB 1000-D2 using the Maximum Value Process solution to analyze samples in real-time. BreathTech Corporation developed the BreathTest-1000 breath analysis tool, but the company has determined to deploy capital instead to other subsidiaries. Pro-Control, Inc. introduced the Pro-Control Maximum Value Processing and the Pro-Control 1000-D2 mass spectrometer for industrial process control. EN-SCAN, Inc. was formed on February 28, 2025, to manufacture instruments for environmental testing, with a lineup including EN-SCAN Handheld GC, EN-SCAN Fenceline Monitor, and EN-SCAN Rugged Lab GC-MS.

In April 2025, Astrotech received a $429,000 ⁷ purchase order for TRACER 1000 explosive trace detectors from Intuitive Research and Technology, a TSA approved contractor, and fulfilled the order by selling six ⁸ TRACER 1000 explosive detectors. On June 12, 2025, the company sold the first sale and deployment of the TRACER 1000 Narcotic Trace Detector in Vietnam. On January 14, 2025, 1st Detect was awarded research and development contract 70RSAT24CB0000015 with the U.S. Department of Homeland Security. On January 29, 2025, the company entered into a new lease agreement for a facility of approximately 17,628 ⁹ square feet in Austin, Texas (the Metric facility) for a term of 89-months, with total contractual base rent obligation of approximately $3.0 million ¹⁰, less a tenant allowance of $317.3 thousand ¹¹. On June 13, 2024, AgLAB and SC Laboratories entered into a master lease agreement for joint marketing of the AgLAB 1000-D2.

For the fiscal year ended June 30, 2025, total revenue was $1,049 thousand ¹², compared to $1,664 thousand ¹³ in the prior year, a decrease of $615 thousand ¹⁴ or 37.0% ¹⁵. Gross profit was $475 thousand ¹⁶ with a gross margin of 45.3% ¹⁷, compared to $751 thousand ¹⁸ and 45.1% ¹⁹ in the prior year. Net loss was $13,850 thousand ²⁰ compared to $11,666 thousand ²¹ in the prior year. Total comprehensive loss was $13,537 thousand ²² compared to $11,390 thousand ²³ in the prior year. Cash and cash equivalents were $3.1 million ²⁴ at June 30, 2025, compared to $10.4 million ²⁵ at June 30, 2024.

A primary growth vector is the expansion of the TRACER 1000 into the U.S. market following TSA approval for air cargo in June 2024, which advanced the TRACER 1000 to Stage II testing. The company has also commenced the process to pass TSA checkpoint testing, involving Developmental Test and Evaluation by the Transportation Security Laboratory. For the fiscal year 2023, the United States federal government had a budget of over 6,000 ²⁶ ETD units at checkpoint and baggage screening points. The company is currently accepting orders for the TRACER 1000 ETD and NTD listed in the GSA IT Schedule 70 under Contract No. GS-35F-250GA. International expansion continues, with units deployed in 34 ²⁷ locations in 16 ²⁸ countries, and the first sale in Vietnam on June 12, 2025.

Another growth vector is the expansion of the AgLAB business in the U.S. hemp and cannabis market, where the wholesale value of the cannabis crop from U.S. states permitting adult-use and medical cannabis exceeds $6 billion ²⁹ annually. During field trials of the AgLAB MVP, the company was able to improve ending-weights yields by 20% ³⁰ or more. The company also launched Pro-Control for industrial process control and EN-SCAN for environmental testing, with the EN-SCAN lineup including three key products. The company intends to use regional sales teams for Pro-Control assigned to geographic territories with a density of manufacturing, noting a high density of food, petrochemical, chemical, and industrial companies within a few hours driving radius of Austin.

The filing does not contain explicit margin trajectory or cost structure targets.

The company expects to relocate to the Metric facility during fiscal year 2026. As of June 30, 2025, the company employed 32 ³¹ employees, none of which were covered by any collective bargaining agreements. The company expects expenses to increase in connection with ongoing activities, particularly as it continues research and development efforts and expands business efforts.

Research and development expenses for the fiscal year ended June 30, 2025 were $8,142 thousand ³², compared to $6,790 thousand ³³ in the prior year. Purchases of property and equipment were $833 thousand ³⁴ for the fiscal year ended June 30, 2025. The company has never paid cash dividends and has no intention of paying dividends in the future. The company's Board of Directors authorized a share repurchase program on November 9, 2022, allowing repurchases of up to $1.0 million ³⁵ of common stock, which was terminated on June 16, 2023.

The company faces headwinds from the lengthy and uncertain regulatory approval processes required for its products. TSA approval is required to begin selling the TRACER 1000 in the United States, and FDA clearance or approval is required to market the BreathTest-1000. The company notes that obtaining approval from both TSA and FDA is a complex and lengthy process. Additionally, the company's AgLAB business is highly dependent on the U.S. hemp and cannabis market, where marijuana remains a Schedule I controlled substance illegal under federal law, creating regulatory, financial, operational and reputational risks.

The company faces constraints from its reliance on third party suppliers, including single source suppliers, for critical components such as specialized cables and specialized pumps. The company does not have supply agreements with certain suppliers beyond purchase orders. International operations expose the company to risks including import and export laws, tariffs, exchange rate fluctuations, political and economic instability, and potential violations of anti-corruption laws. Changes in U.S. trade policy, including tariffs on goods from Canada, Mexico and China, and a pause in processing new export license applications by the Bureau of Industry and Security since early February 2025, could affect the company's ability to export products.

The company has incurred significant losses since inception, with an accumulated deficit of approximately $251 million ³⁶ as of June 30, 2025, and a net loss of $13.8 million ³⁷ for fiscal year 2025. The business units are in the development stage with limited revenues, and it is uncertain whether they will earn any revenues in the future or ultimately be profitable. The company may need to raise additional capital, and there is no assurance it will be able to obtain future financing on commercially reasonable terms. The company's manufacturing operations depend on third party suppliers, including single source suppliers, making it vulnerable to supply shortages and price fluctuations. International sales comprise a significant amount of overall revenue and expose the company to operational, financial and regulatory risks, including import/export laws, tariffs, and exchange rate fluctuations. The company generated substantial revenue from four ³⁸ customers, none of which have a long-term contract, and such high concentration may cause revenue to fluctuate significantly year over year.

Management's message emphasizes the progress made by business units in developing and demonstrating relevant solutions, highlighting fiscal year 2025 announcements including the DHS contract award, the launch of the enhanced TRACER 1000 NTD, the first TSA-approved sale of the TRACER 1000 ETD, the formation of EN-SCAN, and the first sale in Vietnam. Management states that the additional applications of the AMS Technology and growing channel partner relationships create opportunities for revenue growth in subsequent fiscal years. The company has determined to deploy capital to its other subsidiaries rather than BreathTech, which would require many years and significant investment due to regulatory requirements. Management believes that cash and cash equivalents and investments will enable the company to fund operating expenses and capital expenditure requirements for at least twelve months following the date the consolidated financial statements are issued.